Phase 1 Trial of BTM-3566 in Relapsed/Refractory Mature B Cell Lymphomas

The goal of this clinical trial is to learn if BMT-3566 can safety be given to adult patients with relapsed or refractory mature b cell lymphomas. It will also learn how well BTM-3566 works to treat relapsed or refractory mature b cell lymphomas. The main questions it aims to answer are: What are the side effects of BTM-3566 at different doses? What are the levels of BTM-3566 in the blood at different timepoints around dosing? What is the clinical benefit of BTM-3566 in treating cancer (i.e. how well does it slow or stop disease progression)? Participants will: Take BTM-3566 in 14-day perio

Trial Details

NCT ID
NCT06792734
Phase
PHASE1
Sponsor
Bantam Pharmaceuticals
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • BTM-3566
Locations (sample)
  • Charlotte, North Carolina, United States|35.22709,-80.84313
  • Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

  • must be age ≥18 years
  • must have a diagnosis of relapsed or refractory mature B cell lymphoma
  • must have measurable disease per response evaluation criteria in lymphoma (Lugano classification)
  • must have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →